Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ranbaxy Cleared To Launch Diovan Generic In U.S. With Exclusivity

This article was originally published in PharmAsia News

Executive Summary

Ranbaxy Laboratories is free to launch its generic version of the Novartis drug Diovan (valsartan) for treating high blood pressure in the U.S. after gaining U.S. FDA approval.

You may also be interested in...



Sun Pharma’s Ranbaxy Fails In Bid To Dodge Antitrust Suit

A US lawsuit accusing Sun Pharma’s Ranbaxy of violating racketeering and antitrust laws, thereby maintaining artificially inflated prices for three blockbuster drugs, is now set to go to trial in January next year, after a US district court in Massachusetts denied all motions for summary judgment.

FDA Launches New Webpage Dedicated To AR And VR Medical Devices

The US Food and Drug Administration has launched a new webpage dedicated to medical devices that incorporate augmented reality and virtual reality technologies. The agency has approved some 39 AR/VR devices.

Deals Shaping The Medtech And Diagnostics Industry, December 2022

Medtech Insight's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – in vitro diagnostics and medical devices – and then categorized by type – acquisition, alliance, or financing. This month’s column covers deals announced in November 2022. Data provided by Citeline's Biomedtracker.

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC087483

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel